Edition:
India

VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

0.55USD
14 Dec 2017
Change (% chg)

$-0.03 (-5.19%)
Prev Close
$0.58
Open
$0.57
Day's High
$0.57
Day's Low
$0.53
Volume
131,967
Avg. Vol
135,926
52-wk High
$1.40
52-wk Low
$0.53

Latest Key Developments (Source: Significant Developments)

Vivus reports third quarter 2017 financial results
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Vivus Inc :Vivus reports third quarter 2017 financial results.Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​.Vivus Inc - qtrly ‍basic and diluted net loss per share $0.06​.  Full Article

Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
Monday, 3 Oct 2016 

VIVUS Inc : VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales . VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra .VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million.  Full Article

Vivus says extends return date of Stendra commercial rights
Tuesday, 30 Aug 2016 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

Vivus posts qtrly rev $13.8 mln vs $23.0 mln last year
Friday, 5 Aug 2016 

Vivus Inc : Qtrly loss per share $0.11 .Qtrly revenue $13.8 million versus $23.0 million.  Full Article

Vivus Inc says has files lawsuit -- 8-K
Thursday, 28 Jul 2016 

Vivus Inc : Says lawsuit was filed in response to an abbreviated new drug application filed by Hetero .Vivus Inc says has filed lawsuit in U.S. District court for district of New Jersey against Hetero USA, Inc. and Hetero Labs Limited.  Full Article

Vivus says to extend return date of Stendra commercial rights
Friday, 1 Jul 2016 

Vivus Inc : Vivus Inc says to extend return date of Stendra commercial rights .Extension of termination date of license agreement between Auxilium Pharmaceuticals and Vivus for Stendra â U.S. and Canadian commercial rights through August 31.  Full Article

BRIEF-Vivus reports third quarter 2017 financial results

* Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​